Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-crystallin B is a highly stable, water-soluble, monomeric protein encoded by the CRYGB gene in humans and is a dominant structural component of the vertebrate eye lens[1][2][5][6]. It belongs to the beta/gamma-crystallin protein superfamily and plays a crucial role in maintaining lens transparency and the lens’s refractive properties[1][2][6]. Unlike other crystallins, gamma-crystallins such as CRYGB typically lack connecting peptides and terminal extensions, and they are differentially regulated after early development[1]. Mutations or age-related changes in gamma-crystallins, including CRYGB, can lead to lens opacification and cataract formation, but CRYGB is not considered a classical therapeutic target such as a receptor, enzyme, or transporter[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-crystallin B (CRYGB).